skip to Main Content
THCP: Newly Discovered Form of THC Could Help Explain Potency Variations in Cannabis Strains and May Lead to New Product Label Requirements

The pharmacological effects of most cannabinoids remain a mystery. Despite more than 120 identified cannabinoids in the cannabis plant, very few other than THC (tetrahydrocannabinol) and CBD (cannabidiol) have been isolated and characterized in terms of their pharmacological properties. The newest identified cannabinoid is THCP (tetrahydrocannabiphorol) and is many times more potent than THC.

THC is recognized as the primary intoxicating cannabinoid found in the cannabis plant. Studies have shown that the strength of THC’s intoxicating effect is influenced by the length of the side alkyl chain on the molecule. Naturally occurring THC has a five-carbon side chain. Synthetic analogues of THC with a longer side chain bind more tightly to the human cannabinoid receptor CB1and have resulted in intoxicating potency many times higher than naturally occurring THC. A minimum of three carbons is necessary to bind the CB1receptor, and the highest binding activity has been registered with an eight-carbon side chain.

Discovery of THCP

No cannabinoid with a side chain containing more than five carbon atoms has ever been reported as naturally occurring. In a paper published in the journal Scientific Reports on December 30, 2019, however, Italian researchers confirmed the discovery of a naturally occurring cannabinoid with the same structure as THC but with a seven-carbon side chain. This new cannabinoid has been named tetrahydrocannabiphorol, or THCP. It was isolated from a medicinal cannabis variety, the Italian FM2.

THCP May Be 30 Times More Potent than THC

It is expected that THCP will prove to have a high binding affinity for the CB1receptor and a greater intoxicating effect than THC. Initial test results indicate that THCP may have a binding affinity for the CB1receptor more than 30 times higher than THC.

Does THCP Explain Why Cannabis Strains with Similar THC Levels Cause Varied Effects?

The Italian researchers theorize that the presence of THCP could account for the pharmacological properties of some cannabis varieties that are difficult to explain by the presence of THC alone. Though the cannabis variety used for the study has a very low concentration of THCP, other cannabis varieties may contain higher concentrations. The authors point out that “there exists an astonishing variability of subject response to a cannabis-based therapy even with an equal THC dose.” They conclude that this may be due to the effect of extremely active cannabinoids such as THCP, but note that inadequate research has been conducted to date.

Given the potency of THCP, the paper concludes by recommending that THCP be included in the list of the main cannabinoids, along with THC and CBD, when evaluating the pharmacological effects of cannabis varieties.

Will New Product Labels and Warnings Be Needed?

The findings on THCP inevitably raise the questions of whether there are other highly potent cannabinoids that have not yet been identified and whether product label changes will be needed. As cannabinoid science progresses and new compounds are identified, it is likely that product labeling and consumer warnings will become more complex. Most labels on cannabis products currently focus on THC and CBD concentration to the exclusion of other potentially potent cannabinoids. This label practice may need to evolve with the science, and this evolution may start with THCP.

Ian Stewart

Ian Stewart

Ian is a partner in the Los Angeles office of Wilson Elser. He is co-founder and chair of the Wilson Elser Cannabis Law practice and uses his 20 years of legal experience to help clients navigate the legalities around cannabis and hemp. Ian works with licensed cannabis operators to comply with their obligations under the law and to develop risk management best practices. He also regularly consults with insurance companies to assist with cannabis-related underwriting practices and the development of new policy forms.

He is currently Chair of the National Cannabis Industry Association’s Finance and Insurance Committee, as well as Vice-Chair of the California Cannabis Industry Association’s Insurance Committee. Ian received his B.A. from Washington University in St. Louis, and his JD from St. Louis University. He has been with Wilson Elser for the past 18 years.

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Cannabis Legalization and its Impact on the Transportation Industry

Trends in Cannabis Legalization While employers in the transportation industry are acutely aware of the effects COVID-19 has imposed over the last 18 months, another phenomenon has been making itself known: the ever-increasing tally of states and localities across the country legalizing cannabis for medicinal and recreational purposes. A majority of states now have enacted…

German Police’s Move To Stop Adult-Use Cannabis Legalisation A Throwback To Dark Days Of Prohibition

CALLS by the leaders of two German police unions for politicians to U-Turn on the their progressive march towards cannabis legalisation have been roundly condemned. This comes as political talks continue towards the the formation of a cannabis-friendly ‘Traffic-Light Coalition’. It appears that it is just these talks – and the potential for adult-use legalisation…

N.J. announces 14 new medical marijuana licenses, expanding market after long delay

New Jersey has licensed 14 new marijuana businesses, bringing a long-awaited expansion of the state’s medical marijuana program that exceeds original plans. The Cannabis Regulatory Commission on Friday announced the winners of a competitive and burdensome licensing process that began two years ago. Nearly 200 entrepreneurs applied for licenses to grow and sell medical marijuana,…

Cannabis tech startup Dutchie raises $350M to double valuation to $3.75B in less than a year

Dutchie is rolling in the green. The Bend, Ore.-based creators of technology to help facilitate legal cannabis orders has raised $350 million in a Series D funding round, announced Thursday. The influx of new cash comes just seven months after the startup raised $200 million. Dutchie’s valuation has doubled to $3.75 billion. “Cannabis presents opportunities…

More Categories

Back To Top
×Close search